APO Research
Talk to an analyst

APO RESEARCH · REPORT

OTC Anti-Infective Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global OTC Anti-Infective Drug Market Outlook and Growth Opportunities 2026

2 January 2026199 pages

Choose your research edition.

Industry ResearchOTC Anti-Infective Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal OTC Anti-Infective Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal OTC Anti-Infective Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal OTC Anti-Infective Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal OTC Anti-Infective Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global OTC Anti-Infective Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for OTC Anti-Infective Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for OTC Anti-Infective Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for OTC Anti-Infective Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the OTC Anti-Infective Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the OTC Anti-Infective Drug market include Cipla, CR SANJIU, Lingrui, Sun Pharma, Bayer, GSK, MYLAN, NOVARTIS and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global OTC Anti-Infective Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of OTC Anti-Infective Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents OTC Anti-Infective Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global OTC Anti-Infective Drug market.

OTC Anti-Infective Drug Segment by Company

Cipla

CR SANJIU

Lingrui

Sun Pharma

Bayer

GSK

MYLAN

NOVARTIS

Johnson & Johnson

Teva

OTC Anti-Infective Drug Segment by Type

Antiviral

Antibacterial

Antifungal

Antiseptics

Other

OTC Anti-Infective Drug Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

OTC Anti-Infective Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global OTC Anti-Infective Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the OTC Anti-Infective Drug key companies, revenue, market share, and recent developments.

3. To split the OTC Anti-Infective Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions OTC Anti-Infective Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify OTC Anti-Infective Drug significant trends, drivers, influence factors in global and regions.

6. To analyze OTC Anti-Infective Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OTC Anti-Infective Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of OTC Anti-Infective Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OTC Anti-Infective Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global OTC Anti-Infective Drug industry.

Chapter 3: Detailed analysis of OTC Anti-Infective Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of OTC Anti-Infective Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of OTC Anti-Infective Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. OTC Anti-Infective Drug Industry Trends Table 2. OTC Anti-Infective Drug Industry Drivers Table 3. OTC Anti-Infective Drug Industry Opportunities and Challenges Table 4. OTC Anti-Infective Drug Industry Restraints Table 5. Global OTC Anti-Infective Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global OTC Anti-Infective Drug Revenue Share by Company (2021-2026) Table 7. Global OTC Anti-Infective Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global OTC Anti-Infective Drug Key Company Manufacturing Base & Headquarters Table 9. Global OTC Anti-Infective Drug Company, Product Type & Application Table 10. Global OTC Anti-Infective Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global OTC Anti-Infective Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Antiviral Table 15. Significant Companies of Antibacterial Table 16. Significant Companies of Antifungal Table 17. Significant Companies of Antiseptics Table 18. Significant Companies of Other Table 19. Global OTC Anti-Infective Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global OTC Anti-Infective Drug Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global OTC Anti-Infective Drug Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global OTC Anti-Infective Drug Sales Value Share by Type (2021-2026) Table 23. Global OTC Anti-Infective Drug Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Retail Pharmacies Table 25. Significant Companies of Online Pharmacies Table 26. Significant Companies of Hospital Pharmacies Table 27. Global OTC Anti-Infective Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global OTC Anti-Infective Drug Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global OTC Anti-Infective Drug Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global OTC Anti-Infective Drug Sales Value Share by Application (2021-2026) Table 31. Global OTC Anti-Infective Drug Sales Value Share by Application (2027-2032) Table 32. Global OTC Anti-Infective Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global OTC Anti-Infective Drug Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global OTC Anti-Infective Drug Sales Value Share by Region (2021-2026) Table 35. Global OTC Anti-Infective Drug Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global OTC Anti-Infective Drug Sales Value Share by Region (2027-2032) Table 37. Global OTC Anti-Infective Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global OTC Anti-Infective Drug Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global OTC Anti-Infective Drug Sales Value Market Share by Country (2021-2026) Table 40. Global OTC Anti-Infective Drug Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global OTC Anti-Infective Drug Sales Value Market Share by Country (2027-2032) Table 42. Cipla Company Information Table 43. Cipla Business Overview Table 44. Cipla OTC Anti-Infective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Cipla OTC Anti-Infective Drug Product Portfolio Table 46. Cipla Recent Development Table 47. CR SANJIU Company Information Table 48. CR SANJIU Business Overview Table 49. CR SANJIU OTC Anti-Infective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. CR SANJIU OTC Anti-Infective Drug Product Portfolio Table 51. CR SANJIU Recent Development Table 52. Lingrui Company Information Table 53. Lingrui Business Overview Table 54. Lingrui OTC Anti-Infective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Lingrui OTC Anti-Infective Drug Product Portfolio Table 56. Lingrui Recent Development Table 57. Sun Pharma Company Information Table 58. Sun Pharma Business Overview Table 59. Sun Pharma OTC Anti-Infective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Sun Pharma OTC Anti-Infective Drug Product Portfolio Table 61. Sun Pharma Recent Development Table 62. Bayer Company Information Table 63. Bayer Business Overview Table 64. Bayer OTC Anti-Infective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Bayer OTC Anti-Infective Drug Product Portfolio Table 66. Bayer Recent Development Table 67. GSK Company Information Table 68. GSK Business Overview Table 69. GSK OTC Anti-Infective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. GSK OTC Anti-Infective Drug Product Portfolio Table 71. GSK Recent Development Table 72. MYLAN Company Information Table 73. MYLAN Business Overview Table 74. MYLAN OTC Anti-Infective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. MYLAN OTC Anti-Infective Drug Product Portfolio Table 76. MYLAN Recent Development Table 77. NOVARTIS Company Information Table 78. NOVARTIS Business Overview Table 79. NOVARTIS OTC Anti-Infective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. NOVARTIS OTC Anti-Infective Drug Product Portfolio Table 81. NOVARTIS Recent Development Table 82. Johnson & Johnson Company Information Table 83. Johnson & Johnson Business Overview Table 84. Johnson & Johnson OTC Anti-Infective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Johnson & Johnson OTC Anti-Infective Drug Product Portfolio Table 86. Johnson & Johnson Recent Development Table 87. Teva Company Information Table 88. Teva Business Overview Table 89. Teva OTC Anti-Infective Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Teva OTC Anti-Infective Drug Product Portfolio Table 91. Teva Recent Development Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. OTC Anti-Infective Drug Product Image Figure 2. Global OTC Anti-Infective Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global OTC Anti-Infective Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global OTC Anti-Infective Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Antiviral Image Figure 8. Antibacterial Image Figure 9. Antifungal Image Figure 10. Antiseptics Image Figure 11. Other Image Figure 12. Global OTC Anti-Infective Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global OTC Anti-Infective Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global OTC Anti-Infective Drug Sales Value Share by Type (2021-2032) Figure 15. Retail Pharmacies Image Figure 16. Online Pharmacies Image Figure 17. Hospital Pharmacies Image Figure 18. Global OTC Anti-Infective Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global OTC Anti-Infective Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global OTC Anti-Infective Drug Sales Value Share by Application (2021-2032) Figure 21. Global OTC Anti-Infective Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global OTC Anti-Infective Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America OTC Anti-Infective Drug Sales Value (2021-2032) & (US$ Million) Figure 24. North America OTC Anti-Infective Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe OTC Anti-Infective Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Europe OTC Anti-Infective Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific OTC Anti-Infective Drug Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific OTC Anti-Infective Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America OTC Anti-Infective Drug Sales Value (2021-2032) & (US$ Million) Figure 30. South America OTC Anti-Infective Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa OTC Anti-Infective Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa OTC Anti-Infective Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Antiviral
  • Antibacterial
  • Antifungal
  • Antiseptics
  • Other
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Cipla
  • CR SANJIU
  • Lingrui
  • Sun Pharma
  • Bayer
  • GSK
  • MYLAN
  • NOVARTIS
  • Johnson & Johnson
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global OTC Anti-Infective Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global OTC Anti-Infective Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 OTC Anti-Infective Drug Market Dynamics
  1. 2.1 OTC Anti-Infective Drug Industry Trends
  2. 2.2 OTC Anti-Infective Drug Industry Drivers
  3. 2.3 OTC Anti-Infective Drug Industry Opportunities and Challenges
  4. 2.4 OTC Anti-Infective Drug Industry Restraints
3 OTC Anti-Infective Drug Market by Company
  1. 3.1 Global OTC Anti-Infective Drug Company Revenue Ranking in 2025
  2. 3.2 Global OTC Anti-Infective Drug Revenue by Company (2021-2026)
  3. 3.3 Global OTC Anti-Infective Drug Company Ranking (2024-2026)
  4. 3.4 Global OTC Anti-Infective Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global OTC Anti-Infective Drug Company Product Type and Application
  6. 3.6 Global OTC Anti-Infective Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global OTC Anti-Infective Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 OTC Anti-Infective Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 OTC Anti-Infective Drug Market by Type
  1. 4.1 OTC Anti-Infective Drug Type Introduction
  2. 4.1.1 Antiviral
  3. 4.1.2 Antibacterial
  4. 4.1.3 Antifungal
  5. 4.1.4 Antiseptics
  6. 4.1.5 Other
  7. 4.2 Global OTC Anti-Infective Drug Sales Value by Type
  8. 4.2.1 Global OTC Anti-Infective Drug Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global OTC Anti-Infective Drug Sales Value by Type (2021-2032)
  10. 4.2.3 Global OTC Anti-Infective Drug Sales Value Share by Type (2021-2032)
5 OTC Anti-Infective Drug Market by Application
  1. 5.1 OTC Anti-Infective Drug Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global OTC Anti-Infective Drug Sales Value by Application
  6. 5.2.1 Global OTC Anti-Infective Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global OTC Anti-Infective Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global OTC Anti-Infective Drug Sales Value Share by Application (2021-2032)
6 OTC Anti-Infective Drug Regional Value Analysis
  1. 6.1 Global OTC Anti-Infective Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global OTC Anti-Infective Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global OTC Anti-Infective Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global OTC Anti-Infective Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America OTC Anti-Infective Drug Sales Value (2021-2032)
  7. 6.3.2 North America OTC Anti-Infective Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe OTC Anti-Infective Drug Sales Value (2021-2032)
  10. 6.4.2 Europe OTC Anti-Infective Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific OTC Anti-Infective Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific OTC Anti-Infective Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America OTC Anti-Infective Drug Sales Value (2021-2032)
  16. 6.6.2 South America OTC Anti-Infective Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa OTC Anti-Infective Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa OTC Anti-Infective Drug Sales Value Share by Country, 2025 VS 2032
7 OTC Anti-Infective Drug Country-level Value Analysis
  1. 7.1 Global OTC Anti-Infective Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global OTC Anti-Infective Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global OTC Anti-Infective Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global OTC Anti-Infective Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt OTC Anti-Infective Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt OTC Anti-Infective Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt OTC Anti-Infective Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Cipla
  2. 8.1.1 Cipla Company Information
  3. 8.1.2 Cipla Business Overview
  4. 8.1.3 Cipla OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Cipla OTC Anti-Infective Drug Product Portfolio
  6. 8.1.5 Cipla Recent Developments
  7. 8.2 CR SANJIU
  8. 8.2.1 CR SANJIU Company Information
  9. 8.2.2 CR SANJIU Business Overview
  10. 8.2.3 CR SANJIU OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CR SANJIU OTC Anti-Infective Drug Product Portfolio
  12. 8.2.5 CR SANJIU Recent Developments
  13. 8.3 Lingrui
  14. 8.3.1 Lingrui Company Information
  15. 8.3.2 Lingrui Business Overview
  16. 8.3.3 Lingrui OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lingrui OTC Anti-Infective Drug Product Portfolio
  18. 8.3.5 Lingrui Recent Developments
  19. 8.4 Sun Pharma
  20. 8.4.1 Sun Pharma Company Information
  21. 8.4.2 Sun Pharma Business Overview
  22. 8.4.3 Sun Pharma OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sun Pharma OTC Anti-Infective Drug Product Portfolio
  24. 8.4.5 Sun Pharma Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer OTC Anti-Infective Drug Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GSK OTC Anti-Infective Drug Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 MYLAN
  38. 8.7.1 MYLAN Company Information
  39. 8.7.2 MYLAN Business Overview
  40. 8.7.3 MYLAN OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 MYLAN OTC Anti-Infective Drug Product Portfolio
  42. 8.7.5 MYLAN Recent Developments
  43. 8.8 NOVARTIS
  44. 8.8.1 NOVARTIS Company Information
  45. 8.8.2 NOVARTIS Business Overview
  46. 8.8.3 NOVARTIS OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 NOVARTIS OTC Anti-Infective Drug Product Portfolio
  48. 8.8.5 NOVARTIS Recent Developments
  49. 8.9 Johnson & Johnson
  50. 8.9.1 Johnson & Johnson Company Information
  51. 8.9.2 Johnson & Johnson Business Overview
  52. 8.9.3 Johnson & Johnson OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Johnson & Johnson OTC Anti-Infective Drug Product Portfolio
  54. 8.9.5 Johnson & Johnson Recent Developments
  55. 8.10 Teva
  56. 8.10.1 Teva Company Information
  57. 8.10.2 Teva Business Overview
  58. 8.10.3 Teva OTC Anti-Infective Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva OTC Anti-Infective Drug Product Portfolio
  60. 8.10.5 Teva Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst